MannKind (MNKD) After Mixed Earnings Is The Stock Still Undervalued

Why MannKind's latest earnings matter for shareholders

MannKind (MNKD) recently reported second quarter 2026 results that combined higher revenue with a shift back to losses. This mix of topline expansion and weaker profitability is now central to how investors assess the stock.

See our latest analysis for MannKind.

MannKind's recent earnings release has arrived after a period where the stock has swung between pressure and recovery, with a 25.23% 90 day share price return against a weaker year to date share price performance and a modestly positive 1 year total shareholder return of 2.78%. This suggests improving short term momentum, while longer term investors have seen more muted results overall.

If the latest earnings headlines have you rethinking your watchlist, it can help to widen the lens and look at other opportunities through our 42 healthcare AI stocks

MannKind shares have climbed in the short term while still trading well below the average analyst target. The spread between the current US$4.07 price and estimated value ranges is now the key question for the valuation section that follows.

Most Popular Narrative: 46.4% Undervalued

The most followed narrative puts MannKind's fair value at $7.59 a share compared with the latest $4.07 close, which frames the stock as heavily undervalued and turns the spotlight onto the assumptions behind that gap.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are set to accelerate market penetration amid a rising global diabetes burden and an aging population, directly supporting revenue and earnings growth.

Read the complete narrative.

Want to see what is really baked into that fair value for MannKind? Revenue growth, higher profit margins and a richer earnings multiple all matter. The narrative leans on a detailed path to profitability and a higher earnings base. The exact mix and timing of those shifts is where the story gets interesting.

Result: Fair Value of $7.59 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, MannKind's story can change quickly if Afrezza prescription growth remains limited or if reliance on Tyvaso DPI royalties leaves revenue too concentrated.

Find out about the key risks to this MannKind narrative.

Next Steps

With MannKind's narrative pulling in both risks and rewards, it makes sense to move quickly and test the assumptions against your own view using the 3 key rewards and 1 important warning sign

Looking for more MannKind sized investment ideas?

If MannKind is on your radar, do not stop there. Exploring opportunities across different sectors can help you build a more diversified portfolio.

• Identify companies that trade below their estimated value by scanning the 50 high quality undervalued stocks.
• Focus on businesses highlighted in the 79 resilient stocks with low risk scores if you want to prioritise resilience.
• Look for early stage opportunities with solid financial footing through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com